[DOI] [PubMed] [Google Scholar] 140.Dietz K.J., Jacob S., Oelze M.L., Laxa M., Tognetti V., de Miranda S.M., Baier M., Finkemeier I
Across the SUSTAIN program, the primary and confirmatory secondary endpoints for most trials were change from baseline in HbA 1c and body weight, respectively, to the end of treatment (30, 40, 52, or 56 weeks) ( 1c and body weight, respectively (32)
Future research will focus on overcoming in vivo delivery challenges and elucidating the comprehensive molecular network influenced by pDNA/Polybia-MP1 to pave the way for its clinical application
Modern GLP-1 medications have largely replaced older options because they deliver superior outcomes with better long-term safety profiles and sustained efficacy
Nucleotide sequence of the cloned human preproglucagon gene, along with the relevant deduced amino acid sequences, as hand-annotated by Mojsov during the early days of her time at MGH
They also help form red blood cells